Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06919965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableLead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLCStudy sites: 113 to 114 · Eligibility criteria expanded, about 11 words · Secondary endpoints: details revised at 9 of 13 entriesShow 3 more changesShow less
Study sites: 113 to 114
Eligibility criteria expanded, about 11 words
Secondary endpoints: details revised at 9 of 13 entries
MinorStudy sites: 112 to 113v20
MinorStudy sites: 110 to 112v19
MinorStudy sites: 109 to 110v18
MinorStudy sites: 108 to 109v17
MinorTrial sites expanded: 104 → 108 locationsv16
MinorStudy sites: 102 to 104v15
MinorStudy sites: 88 to 102v14
MinorStudy sites: 77 to 88v13
MinorStudy sites: 53 to 77v12
MinorStudy sites: 38 to 53v11
NotablePrimary completion date: Aug 13, 2027 to Apr 6, 2028Study sites: 13 to 38v10Show 1 more changeShow less
Study sites: 13 to 38
MinorStudy sites: 3 to 13v9
NotableTrial status: Not Yet Recruiting to RecruitingStart date changed from estimate of Sep 22, 2025 to Sep 10, 2025 · Site details revised at 3 of 3 sitesv8Show 2 more changesShow less
Start date changed from estimate of Sep 22, 2025 to Sep 10, 2025
Site details revised at 3 of 3 sites
MinorStudy sites: 0 to 3v7
MinorStart date: Sep 30, 2025 to Sep 22, 2025v6
MinorRe-verified, no change to tracked fieldsv5
MinorStart date: Oct 3, 2025 to Sep 30, 2025v4
NotableStart date: Aug 25, 2025 to Oct 3, 2025Completion date: Feb 5, 2032 to Mar 16, 2032v3Show 1 more changeShow less
Completion date: Feb 5, 2032 to Mar 16, 2032
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).